Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes

被引:63
作者
Cavelti-Weder, Claudia [1 ]
Timper, Katharina [1 ]
Seelig, Eleonora [1 ]
Keller, Cornelia [2 ]
Osranek, Martin [2 ]
Lassing, Ute [3 ]
Spohn, Gunther [3 ]
Maurer, Patrik [3 ]
Mueller, Philipp [3 ]
Jennings, Gary T. [3 ]
Willers, Joerg [3 ]
Saudan, Philippe [3 ]
Donath, Marc Y. [1 ]
Bachmann, Martin F. [3 ]
机构
[1] Univ Basel Hosp, Dept Endocrinol Diabet & Metab, Petersgraben 4, CH-4031 Basel, Switzerland
[2] Univ Zurich Hosp, Dept Diabet Endocrinol & Metab, CH-8091 Zurich, Switzerland
[3] Cytos Biotechnol AG, Schlieren, Switzerland
关键词
RECOMBINANT HUMAN INTERLEUKIN-1-BETA; VIRUS-LIKE PARTICLES; PHASE-I SAFETY; DOUBLE-BLIND; TOXIC MYELODEPRESSION; PRECLINICAL EFFICACY; CONTROLLED-TRIAL; CANCER-PATIENTS; CHEMOTHERAPY; DISEASES;
D O I
10.1038/mt.2015.227
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Interleukin-1 beta (IL-1 beta) is a key cytokine involved in inflammatory illnesses including rare hereditary diseases and common chronic inflammatory conditions as gout, rheumatoid arthritis, and type 2 diabetes mellitus, suggesting reduction of IL-1 beta activity as new treatment strategy. The objective of our study was to assess safety, antibody response, and preliminary efficacy of a novel vaccine against IL-1 beta. The vaccine hIL1bQb consisting of full-length, recombinant IL-1 beta coupled to virus-like particles was tested in a preclinical and clinical, randomized, placebo-controlled, double-blind study in patients with type 2 diabetes. The preclinical simian study showed prompt induction of IL-1 beta-specific antibodies upon vaccination, while neutralizing antibodies appeared with delay. In the clinical study with 48 type 2 diabetic patients, neutralizing IL-1 beta-specific antibody responses were detectable after six injections with doses of 900 mu g. The development of neutralizing antibodies was associated with higher number of study drug injections, lower baseline body mass index, improvement of glycemia, and C-reactive protein (CRP). The vaccine hIL1bQb was safe and well-tolerated with no differences regarding adverse events between patients receiving hIL1bQb compared to placebo. This is the first description of a vaccine against IL-1 beta and represents a new treatment option for IL-1 beta-dependent diseases such as type 2 diabetes mellitus
引用
收藏
页码:1003 / 1012
页数:10
相关论文
共 23 条
  • [1] A vaccine for hypertension based on virus-like particles:: preclinical efficacy and phase I safety and immunogenicity
    Ambuehl, Patrice M.
    Tissot, Alain C.
    Fulurija, Alma
    Maurer, Patrik
    Nussberger, Juerg
    Sabat, Robert
    Nief, Vera
    Schellekens, Charlotte
    Sladko, Katja
    Roubicek, Kirsten
    Pfister, Thomas
    Rettenbacher, Manfred
    Volk, Hans-Dieter
    Wagner, Frank
    Mueller, Philipp
    Jennings, Gary T.
    Bachmann, Martin F.
    [J]. JOURNAL OF HYPERTENSION, 2007, 25 (01) : 63 - 72
  • [2] Opinion - Therapeutic vaccination for chronic diseases: a new class of drugs in sight
    Bachmann, MF
    Dyer, MR
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) : 81 - 88A
  • [3] High-avidity autoantibodies to cytokines
    Bendtzen, K
    Hansen, MB
    Ross, C
    Svenson, M
    [J]. IMMUNOLOGY TODAY, 1998, 19 (05): : 209 - 211
  • [4] Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
    Cavelti-Weder, Claudia
    Babians-Brunner, Andrea
    Keller, Cornelia
    Stahel, Marc A.
    Kurz-Levin, Malaika
    Zayed, Hany
    Solinger, Alan M.
    Mandrup-Poulsen, Thomas
    Dinarello, Charles A.
    Donath, Marc Y.
    [J]. DIABETES CARE, 2012, 35 (08) : 1654 - 1662
  • [5] A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial
    Cornuz, Jacques
    Zwahlen, Susanne
    Jungi, Walter Felix
    Osterwalder, Joseph
    Klingler, Karl
    van Melle, Guy
    Bangala, Yolande
    Guessous, Idris
    Mueller, Philipp
    Willers, Joerg
    Maurer, Patrik
    Bachmann, Martin F.
    Cerny, Thomas
    [J]. PLOS ONE, 2008, 3 (06):
  • [6] Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
    Dinarello, Charles A.
    Simon, Anna
    van der Meer, Jos W. M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (08) : 633 - 652
  • [7] Targeting inflammation in the treatment of type 2 diabetes: time to start
    Donath, Marc Y.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (06) : 465 - 476
  • [8] A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation
    Elkordy, M
    Crump, M
    Vredenburgh, JJ
    Petros, WP
    Hussein, A
    Rubin, P
    Ross, M
    Gilbert, C
    Modlin, C
    Meisenberg, B
    Coniglio, D
    Rabinowitz, J
    Laughlin, M
    Kurtzberg, J
    Peters, WP
    [J]. BONE MARROW TRANSPLANTATION, 1997, 19 (04) : 315 - 322
  • [9] Gershanovich ML, 2001, EUR CYTOKINE NETW, V12, P671
  • [10] Gershanovich ML, 2001, EUR CYTOKINE NETW, V12, P664